Eloxx Pharmaceuticals, Inc. cash flow to debt ratio of 0.00% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Eloxx Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Eloxx Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Eloxx Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Eloxx Pharmaceuticals, Inc. has a net cash position, so leverage is healthy.

Interest expense is not separately reported in Eloxx Pharmaceuticals, Inc.'s latest filing, so interest coverage cannot be calculated.

Eloxx Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Eloxx Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Eloxx Pharmaceuticals, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Eloxx Pharmaceuticals, Inc.'s return on equity of 72.03%, is higher than 15.00%, indicating good performance

Eloxx Pharmaceuticals, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Eloxx Pharmaceuticals, Inc. has insufficient public price history to evaluate earnings stability.

Eloxx Pharmaceuticals, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Eloxx Pharmaceuticals, Inc. has a free cash flow yield of 0.00%, which is below the 2.00% threshold, indicating limited cash return relative to market value

Eloxx Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Eloxx Pharmaceuticals, Inc. has insufficient data to evaluate this check.

ROIC 66.15% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Eloxx Pharmaceuticals, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Eloxx Pharmaceuticals, Inc. has insufficient public price history to evaluate revenue consistency.

Eloxx Pharmaceuticals, Inc. has insufficient public price history to evaluate ROE consistency.

Eloxx Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Eloxx Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Eloxx Pharmaceuticals, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Eloxx Pharmaceuticals, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Eloxx Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Eloxx Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Eloxx Pharmaceuticals, Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails

Eloxx Pharmaceuticals, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue